24
Participants
Start Date
October 22, 2018
Primary Completion Date
November 30, 2020
Study Completion Date
January 30, 2021
Letrozole
Letrozole 2.5 mg by mouth daily for 24 weeks
Palbociclib
Palbociclib 125mg by mouth daily for 21 days per 28-day cycle (21 days on, 7 days off) for 24 weeks
Goserelin
Goserelin 3.6mg subcutaneous injection x 1 on Day 1 of each 28-day cycle for 24 weeks
Oncotype DX Breast Recurrence Score
Prior to assignment to Arm 1 the Oncotype DX diagnostic test will be conducted on diagnostic tissue to assign a recurrence score for stratification to cohort 1 or 2.
West Virginia University, Morgantown
Froedtert Hospital, Milwaukee
Avera Cancer Institute-Sioux Falls, Sioux Falls
Cancer Care Specialists of Central Illinois, Decatur
Lester and Sue Smith Breast Center, Houston
Coast Hematology-Oncology Associates Medical Group, Long Beach
Long Beach Memorial Medical Center, Long Beach
Oncology Hematology Consultants, Long Beach
Saddleback Memorial Medical Center, Laguna Hills
Breast Cancer Care Specialist, Fountain Valley
Orange Coast Blood and Cancer Care, Fountain Valley
Centre Hospitalier de l'Universite de Montreal, Montreal
Jewish General Hospital - Montreal, Montreal
McGill University Health Centre-Cedars Cancer Centre, Montreal
CHU de Quebec - Hopital de Saint-Sacrement, Québec
Collaborators (2)
Genomic Health®, Inc.
INDUSTRY
Pfizer
INDUSTRY
NSABP Foundation Inc
NETWORK